Tentative Approval for New Insulin Glargine
(MedPage Today) -- The FDA has tentatively approved Eli Lilly's "biosimilar" insulin glargine (Basaglar), but it won't be on the market until the company resolves patent litigation with Sanofi. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - August 20, 2014 Category: Cardiology Source Type: news
Temporary Approval for New Insulin Glargine
(MedPage Today) -- The FDA has temporarily approved Eli Lilly's "biosimilar" insulin glargine (Basaglar), but it won't be on the market until the company resolves patent litigation with Sanofi. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - August 20, 2014 Category: Primary Care Source Type: news
Lupin inks pact with South Korean firm to launch diabetes drug
As per the strategic distribution pact inked between the two companies, Mumbai-based Lupin will launch LG Life Sciences' Insulin Glargine. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - August 6, 2014 Category: Pharmaceuticals Source Type: news
Sanofi Files Suit Against Eli Lilly over Insulin Patents
Sanofi's lawsuit came after Lilly and Boehringer Ingelheim had applied with the U.S. FDA to sell a generic version of Lantus (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - July 9, 2014 Category: Pharmaceuticals Source Type: news
Sanofi Submits U300 Insulin to FDA
(MedPage Today) -- The FDA has accepted Sanofi's new drug application for an upgraded formulation of its insulin glargine (Lantus), which is set to come off patent next year. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - July 9, 2014 Category: Cardiology Source Type: news
Sanofi Sues Eli Lilly Over Insulin Rival to LantusSanofi Sues Eli Lilly Over Insulin Rival to Lantus
Sanofi SA, whose top-selling Lantus helps diabetics control blood sugar levels, has filed a lawsuit accusing Eli Lilly and Co of infringing seven patents related to insulin and devices used to deliver it. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 9, 2014 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Basal insulin Toujeo® New Drug Application accepted
The U.S. Food and Drug Administration has accepted for review a New Drug Application for Toujeo® (insulin glargine [rDNA origin] injection, 300 U/ml), an investigational basal insulin. (Source: Pharmacy Europe)
Source: Pharmacy Europe - July 8, 2014 Category: Drugs & Pharmacology Authors: AMcculloch Tags: *** Editor's Pick Diabetes investigational basal insulin Latest News sanofi Toujeo Source Type: news
Lilly wins EU backing for copy of Sanofi's top insulin Lantus
LONDON (Reuters) - European regulators have for the first time recommended approval of a copycat insulin for diabetics, posing a threat to French drugmaker Sanofi SASY.PA whose top-selling Lantus is now set to face a cheaper rival in 2015. (Source: Reuters: Health)
Source: Reuters: Health - June 27, 2014 Category: Consumer Health News Tags: healthNews Source Type: news
ADA: New Insulin as Effective as Lantus (CME/CE)
SAN FRANCISCO (MedPage Today) -- A new insulin glargine product proved to be noninferior to the top-selling Lantus in patients with type 1 and type 2 diabetes, researchers reported here. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - June 16, 2014 Category: Cardiology Source Type: news
ADA: Novel Insulin as Effective as Lantus (CME/CE)
SAN FRANCISCO (MedPage Today) -- A new insulin glargine product proved to be noninferior to the top-selling Lantus in patients with type 1 and type 2 diabetes, researchers reported here. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - June 16, 2014 Category: Cardiology Source Type: news
ADA: Novel Insulin Offers Similar Results as Lantus
SAN FRANCISCO (MedPage Today) -- A new insulin glargine product proved to be noninferior to the top-selling Lantus in patients with type 1 and type 2 diabetes, researchers reported here. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - June 15, 2014 Category: Cardiology Source Type: news
New Post-Hoc Analysis Shows Patients with Type 2 Diabetes Undergoing Intensification of Insulin Therapy Experienced Less Nighttime Hypoglycemia While Being Treated with JANUVIA® (sitagliptin) Compared to Placebo
Dateline City:
WHITEHOUSE STATION
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a post-hoc analysis showing that patients with type 2 diabetes having treatment intensified with insulin glargine therapy while also being treated with JANUVIA® (sitagliptin) 100 mg once-daily had a lower incidence of nighttime (nocturnal) hypoglycemia compared to patients also receiving placebo. Results were presented at the American Diabetes Association 74th Scientific Sessions.
Language:
En...
Source: Merck.com - Research and Development News - June 14, 2014 Category: Pharmaceuticals Tags: Research and Development News Source Type: news
AstraZeneca's Bydureon achieves better glycaemic control than insulin glargine in type 2 diabetes
UK-based AstraZeneca has reported results from its longest, randomised, head-to-head DURATION-3 trial of exenatide once-weekly, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes in adult patients uncontrolle… (Source: Drug Development Technology)
Source: Drug Development Technology - June 1, 2014 Category: Pharmaceuticals Source Type: news
Lilly's diabetes drug better than Sanofi's in late-stage trials
(Reuters) - Eli Lilly and Co said its type 2 diabetes drug was more effective than Sanofi SA's approved drug Lantus in reducing patients' blood sugar levels in three late-stage trials. (Source: Reuters: Health)
Source: Reuters: Health - May 12, 2014 Category: Consumer Health News Tags: healthNews Source Type: news
